BioPorto ProNephro AKITM FDA 510(k) Clearance 2023

BioPorto announced FDA 510(k) marketing clearance for ProNephro AKITM (NGAL), a diagnostic solution for pediatric acute kidney injury risk assessment. The presentation covers the company's advances in early kidney injury detection technology as of December 2023.